Coya Therapeutics - COYA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 75.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.00
▼ -0.44 (-5.21%)

This chart shows the closing price for COYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coya Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COYA

Analyst Price Target is $14.00
▲ +75.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Coya Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 75.00% upside from the last price of $8.00.

This chart shows the closing price for COYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Coya Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2024Chardan CapitalBoost TargetBuy ➝ Buy$11.00 ➝ $14.00Low
8/9/2023Chardan CapitalReiterated RatingBuy ➝ Buy$11.00Low
6/7/2023Chardan CapitalBoost Target$9.00 ➝ $11.00Low
5/18/2023BTIG ResearchInitiated CoverageBuyLow
3/30/2023Chardan CapitalReiterated RatingBuy$9.00Low
3/22/2023Chardan CapitalReiterated RatingBuy$9.00Low
1/26/2023Chardan CapitalInitiated CoverageBuy$9.00N/A
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/23/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/22/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/20/2024
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/20/2024

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Coya Therapeutics logo
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $8.00
Low: $7.81
High: $8.70

50 Day Range

MA: $9.09
Low: $6.82
High: $10.13

52 Week Range

Now: $8.00
Low: $3.21
High: $10.69

Volume

54,152 shs

Average Volume

71,014 shs

Market Capitalization

$116.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Coya Therapeutics?

The following equities research analysts have issued reports on Coya Therapeutics in the last twelve months: BTIG Research, and Chardan Capital.
View the latest analyst ratings for COYA.

What is the current price target for Coya Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Coya Therapeutics in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 75.0%. Chardan Capital has the highest price target set, predicting COYA will reach $14.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $14.00 for Coya Therapeutics in the next year.
View the latest price targets for COYA.

What is the current consensus analyst rating for Coya Therapeutics?

Coya Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COYA will outperform the market and that investors should add to their positions of Coya Therapeutics.
View the latest ratings for COYA.

What other companies compete with Coya Therapeutics?

How do I contact Coya Therapeutics' investor relations team?

The company's listed phone number is 800-587-8170 and its investor relations email address is [email protected]. The official website for Coya Therapeutics is www.coyatherapeutics.com. Learn More about contacing Coya Therapeutics investor relations.